Home Biosimilar Antibodies GPCR & G Protein Others Galcanezumab (Anti-CALCA / CGRP)
For research use only. Not for use in humans.

Galcanezumab (Anti-CALCA / CGRP)

Synonyms: CALCA,CALC1

Galcanezumab (Anti-CALCA/CGRP) is a humanized IgG4 monoclonal antibody targeting the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. MW:145.5 KD.

Galcanezumab (Anti-CALCA / CGRP)

Quality Control

Batch: A257701 Purity: 99% Protein concentration: 3.56mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Galcanezumab (Anti-CALCA/CGRP) is a humanized IgG4 monoclonal antibody targeting the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. MW:145.5 KD.

Product Details

CAS No. 1578199-75-3
Molecular Weight 145.5 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07655440 NOT_YET_RECRUITING Drug: Galcanezumab|Drug: Erenumab 70 mg|Drug: Eptinezumab|Dr Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine Stanford University 2026-07 PHASE4
NCT07040813 RECRUITING Drug: CGRP mAbs and onabotulinumtoxin A|Drug: CGRP mAbs and Migraine; Chronic Migraine Headache Oslo University Hospital 2025-06-06 PHASE3
NCT06401642 RECRUITING Drug: Zavegepant Migraine Mayo Clinic 2024-03-22 PHASE4
NCT07323927 RECRUITING Drug: Galcanezumab Alzheimer Disease Xuanwu Hospital, Beijing 2025-08-01 EARLY_PHASE1
NCT07453576 RECRUITING Drug: Sodium Hypochlorite 1% Irrigation|Drug: Sodium Hypochl Persistent Apical Periodontitis KEZBAN MELTEM ÇOLAK 2025-10-01
NCT07594769 COMPLETED Drug: ODT2 Test formulation|Drug: ODT Reference formulation Migraine Pfizer 2026-05-11 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.